1. Pink Sheet
  2. >>Compliance
  3. >>Distribution/Supply Chain

Pfizer’s Bourla: State of US Presidential Transition Not ‘Ideal’ For Vaccine Rollout

 
• By Sarah Karlin-Smith

Pfizer and BioNTech have accumulated enough safety data to submit an emergency use authorization, and Pfizer CEO Bourla says at the Stat Summit that he is ‘comfortable’ US distribution of the vaccine will go well despite the unusually complicated government transition.

Pfizer CEO Albert Bourla discussed the company's COVID-19 vaccine on 17 November • Source: STAT Summit

Pfizer Inc. CEO Albert Bourla said the current state of the US presidential transition is not the “ideal” situation for rolling out a massive COVID-19 vaccination campaign but remained “comfortable” that the distribution of the company’s vaccine, partnered with BioNTech SE, will go well.

President-elect Joe Biden and his transition team are right now limited in their ability to receive information from the current government due to refusal of the Trump administration to declare that Biden has won the election

More from Distribution/Supply Chain

Switzerland Simplifies Imports Of Unauthorized Drugs To Tackle Drug Shortages

 
• By Eliza Slawther

Swiss authorities have introduced temporary measures that will make it easier for health care professionals to import medicines that are either not authorized or not available in Switzerland, which will particularly benefit pediatric drugs, in light of ongoing shortages.

Companies Advised To Assess Potential Impacts Of Landmark Global Pandemic Treaty

 
• By Neena Brizmohun

Mechanisms in the draft treaty that the more than 190 member states of the World Health Organization have finally agreed to are expected to “materially affect companies,” particularly those that develop, manufacture or distribute pandemic-related health care products.

Beyond Tariffs: The Silver Lining Of The US Pharma Security Investigation

 
• By Jessica Merrill

An investigation by the US Secretary of Commerce into pharmaceutical imports gives industry an opportunity to comment. AAM CEO John Murphy talked to Pink Sheet's sister publication Scrip about the latest developments.

Pharma Still Nervous While Riding Trump’s Tariff Rollercoaster

 
• By Jessica Merrill

The rollout of Trump’s plan has been a policy whiplash, but despite a 90-day pause on tariffs, the US president still appears to be holding a grudge with industry over drug pricing.

More from Compliance